In vivo mutagenicity and hepatocarcinogenicity of 2-amino-3,8- dimethylimidazo[4,5-f]quinoxaline (MeIQx) in bitransgenic c-myc/λlacZ mice

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2587-2592

  Ryu, Doug Young ^a   Pratt, Valerie S W ^a   Davis, Cindy D ^a,c   Schut, Herman A J ^b   Snyderwine, Elizabeth G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3,8 DIMETHYLIMIDAZO[4,5 F]QUINOXALINE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DNA ADDUCT; DRUG EFFECT; GENE FREQUENCY; GENE MUTATION; LIVER CARCINOGENESIS; METABOLIC ACTIVATION; MOUSE; MUTAGENICITY; NONHUMAN; ONCOGENE C MYC; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENS; DNA ADDUCTS; FEMALE; LAC OPERON; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, INBRED DBA; MICE, TRANSGENIC; MUTAGENS; QUINOXALINES; SEQUENCE ANALYSIS, DNA; SEX FACTORS;

EID: 0033152946     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Layton, D. W., Bogen, K. T., Knize, M. G., Hatch, F. T., Johnson, V. M., and Felton, J. S. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis (Lond.), 16: 39-52, 1995.
2. Ohgaki, H., Hasegawa, H., Suenaga, M., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in mice of a mutagenic compound 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) from cooked foods. Carcinogenesis (Lond.), 8: 665-668, 1987.
3. Davis, C. D., Schut, H. A. J., Adamson, R. H., Thorgeirsson, U. P., Thorgeirsson, S. S., and Snyderwine, E. G. Mutagenic activation of IQ, PhIP and MeIQx by hepatic microsomes from rat, monkey and man: low mutagenic activation of MeIQx in cynomolgus monkeys in vitro reflects low DNA adduct levels in vivo. Carcinogenesis (Lond.), 14: 61-65, 1993.
4. 32P-Postlabeling analysis of IQ, MeIQx and PhIP adducts formed in vitro in DNA and polynuceotides and found in vivo in hepatic DNA from IQ-, MeIQx and PhIP-treated monkeys. Carcinogenesis (Lond.), 14: 1389-1395, 1993.
5. 2 atoms of guanine. Chem. Res. Toxicol., 5: 479-490, 1992.
6. 32P-postlabeling method, in the liver of rats fed MeIQx. Carcinogenesis (Lond.), 14: 2165-2170, 1993.
7. Sugimura, T. Overview of carcinogenic heterocyclic amines. Mutat. Res., 376: 211-219, 1997.
8. Felton, J. S., and Knize, M. G. Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat. Res., 259: 205-217, 1991.
9. Watanabe, M., and Ohta, T. Analysis of mutational specificity induced by heterocyclic amines in the lacZ gene of Escherichia coli. Carcinogenesis (Lond.), 14: 1149-1153, 1993.
10. Solomon, M. S., Morgenthaler, P. L., Turesky, R. J., and Essigmann, J. M. Mutational, and DNA binding specificity of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. J. Biol. Chem., 271: 18368-18374, 1996.
11. Knasmuller, S., Kienzi, H., Huber, W., and Hermann, R. S. Organ-specific distribution of genotoxic effects in mice exposed to cooked food mutagens. Mutagenesis, 7: 235-241, 1992.
12. Davis, C. D., Dacquel, E. J., Schut, H. A. J., Thorgeirsson, S. S., and Snyderwine, E. G. In vivo mutagenicity and DNA adduct levels of heterocyclic amines in Muta mice and c-myc/lacZ double transgenic mice. Mutat. Res., 356: 287-296, 1996.
13. Endo, H., Schut, H. A. J., and Snyderwine, E. G. Mutagenic specificity of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-1-methyl-6-phenylimioazo[4,5-f)]pyridine in the supF shuttle vector system. Cancer Res., 54: 3745-3751, 1994.
14. Grisham, J. W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis (Lond.), 18: 59-81, 1997.
15. Facchini, L. M., and Penn, L. Z. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J., 12: 633-651, 1998.
16. Packham, G., and Cleveland, J. L. c-Myc and apoptosis. Biochim. Biophys. Acta, 1242: 11-28, 1995.
17. Sandgren, E. P., Quaife, C. J., Pinkert, C. A., Palmiter, C. D., and Brinster, R. L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene, 4: 715-724, 1989.
18. Murakami, H., Sanderson, N. D., Nagy, P., Marino, P. A., Merlino, G., and Thorgeirsson, S. S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor α in hepatic oncogenesis. Cancer Res., 53: 1719-1723, 1993.
19. Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. Myc, and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.
20. Frith, C. H., Ward, J. M., and Turosov, V. S. Tumours of the liver. In: V. Turosov and U. Mohr (eds.), Pathology of Tumors in Laboratory Animals, vol. 2, Tumours of the Mouse, pp. 223-270. Lyon, France: IARC Scientific, 1994.
21. Gupta, R. C., Earley, K., and Sharma, S. Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc. Nad. Acad. Sci. USA, 85: 3513-3517, 1988.
22. 32P-postlabeling analysis of DNA adducts persisting for up to 42 weeks in skin, epidermis and dermis of mice treated topically with 7,12-dirnethylbenz[α]anthracene. Carcinogenesis (Lond.), 6: 1117-1126, 1985.
23. Vijg, J., and Douglas, G. R. Bacteriophage A and plasmid lacZ transgenic mice for studying mutations in vivo. In: G. P. Pfeiffer (ed.), Technologies for Detection of DNA Damage and Mutations, pp. 391-410. New York: Plenum, 1996.
24. Dean, S. W., and Myhr, B. Measurement of gene mutations in vivo using Muta™ Mouse and positive selection for LacZ phage. Mutagenesis, 9: 183-135, 1994.
25. Shapiro, B. H., Agarwal, A. K., and Pampori, N. A. Gender differences in drug metabolism regulated by growth hormone. Int. J. Biochem. Cell Biol., 27: 9-20, 1995.
26. Gossen, J. A., de Leeuw, W. J. F., Verwest, A., Lohman, P. H. M., and Vijg, J. High somatic mutation frequencies in a LacZ transgene integrated on the mouse X-chromosome. Mutat. Res., 250: 423-429, 1991.
27. Hemminki, K. DNA adducts, mutations and cancer. Carcinogenesis (Lond.), 14: 2007-2012, 1993.
28. Loeb, L. A. Many mutations in cancers. Cancer Surv., 28: 329-342, 1996.
29. Lotze, M. T., Flickinger, J. C., and Carr, B. I. Hepatobiliary neoplasms. In: V. T. Devita, Jr., S. Hellman, and S. T. Bosenberg, Jr. (eds.), Cancer: Principle and Practice of Oncology, Ed. 4, pp. 883-914. Philadelphia: Lippincott, 1993.
30. Blanck, A., Hansson, T., Eriksson, L. C., and Gustafsson, J. A. On mechanisms of sex differences in chemical carcinogenesis: effects of implantation of ectopic pituitary grafts on the early stages of liver carcinogenesis in the rat. Carcinogenesis (Lond.), 5: 1257-1262, 1984.
31. Hsiao, W. L., Castro, M., Giezentanner, J., Fan, H., and Hanecak, R. Acquisition of responsiveness to chemical carcinogens by rodent embryo fibroblasts expressing high levels of the c-myc proto-oncogene. Mol. Carcinogenesis, 5: 140-154, 1992.
32. Santoni-Rugiu, E., Preisegger, K. H., Kiss, A., Audolfsson, T., Shiota, G., Schmidt, E. V., and Thorgeirsson, S. S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc. Natl. Acad. Sci. USA, 93: 9577-9582, 1996.
33. Chernova, O. B., Chernov, M. V., Ishizaka, Y., Agarwal, M. L., and Stark, G. R. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell. Biol., 18: 536-545, 1998.
34. Mai, S., Hanley-Hyde, J., and Fluri, M. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene, 12: 277-288, 1996.
35. Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. Myc, and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.